ClinicalTrials.gg
CompletedNCT00666796Updated Feb 2, 2021

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

A Phase 4 interventional study of Placebo ethanol and Ethanol in Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in United States. Open to participants aged 21 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.

Enrollment
12th of 14
20 · median 283
Started
2005
with 2 others
Phase 4
Only one
of the 14
Registered
3rd of 14
by date
Lead sponsor
9 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one is the 12th largest by enrollment, is one of 3 that started in 2005, is the only one in phase 4, and was the 3rd registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 21 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders as a file.
02

Study summary

The purpose of this study is to assess the pharmacodynamic interaction between gabapentin and ethanol

03

Conditions studied

04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteers in good health aged 21 to 50 (inclusive) years who weigh 50 to 100 kg (110-220 lbs.)
  • Experience with alcohol, defined as mild to moderate use of alcohol, ie, maximum of 14 alcoholic drinks per week

Exclusion criteria

Exclusion Criteria:

  • Recent history (within 2 years) of, or current treatment for, a sleeping disorder including excessive snoring, obstructive sleep apnea or a chronic painful condition
  • Recent history (within 2 years) of, or clinical evidence of significant unstable or uncontrolled respiratory (including asthma and congestive obstructive pulmonary disease), cardiovascular, gastrointestinal, hepatic, renal, endocrine, neurologic (including seizures), psychiatric or other chronic disease
  • History of alcoholism or drug abuse; recreational drug use within the past 30 days; use of benzodiazepines, Ambien®, Sonata®, antidepressants or psychoactive medication within 30 days prior to screening; use of any other sedative, hypnotic, antihistamine, anticholinergic, melatonin, DHEA or herbal sleep/relaxation remedy within 7 days prior to screening
05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    A

    Drug: Placebo ethanol · Drug: Placebo

  • Experimental
    B

    Drug: Ethanol · Drug: Gabapentin

  • Experimental
    C

    Drug: Ethanol · Drug: Placebo

  • Experimental
    D

    Drug: Gabapentin · Drug: Placebo ethanol

Interventions

  • DrugPlacebo ethanol

    Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint

  • Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint

  • DrugPlacebo

    Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint

  • Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint

  • Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint

  • DrugPlacebo

    Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint

  • Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint

  • DrugPlacebo ethanol

    Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint

06

What researchers measure

Primary outcomes

  1. Change from pre-dose in the Psychomotor Vigilance Task (PVT) for completed subjects

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Change from pre-dose in DSST for Intent-to-Treat (ITTI subjects

    Time frame: 2 and 6 hours post-dose

  2. Change from pre-dose in PVT for ITT subjects

    Time frame: 2 and 6 hours post-dose

  3. Change from pre-dose in Buschke Selective Reminding Test (BSRT) for completed subjects

    Time frame: 2 and 6 hours post-dose

  4. Change from pre-dose in BSRT for ITT subjects

    Time frame: 2 and 6 hours post-dose

  5. Change from pre-dose in Stanford Sleepiness Scale (SSS) for completed subjects

    Time frame: 2, 6, and 7.5 hours post-dose

  6. Change from pre-dose in SSS for ITT subjects

    Time frame: 2, 6, and 7.5 hours post-dose

  7. Adverse events

    Time frame: Throughout study duration

  8. Vital signs

    Time frame: Throughout study duration

  9. Change from pre-dose in PVT for completed subjects

    Time frame: 6 hours post-dose

  10. Change from pre-dose in Digit Symbol Substitution Test (DSST) for completed subjects

    Time frame: 2 and 6 hours post-dose

07

Study locations

1 site
  • Pfizer Investigational Site
    Miami, Florida 33181, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2008
First posted
Apr 25, 2008
Start
Apr 2005
CompletionActual
May 2005
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00666796
Responsible party
Sponsor
First posted
Apr 25, 2008
Start date
Apr 2005
Completion
May 2005
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ethanol · Gabapentin

Start the discussion